Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
Ovarian cancer is the fifth most common malignancy with approximately 22,000 newly diagnosed cases each year in the USA. Standard of care after cytoreductive surgery is the application of carboplatin and paclitaxel. The newly developed anti-idiotypic monoclonal antibody abagovomab demonstrated promising results in Phase I/II trials. This new type of drug is currently being tested in a Phase II/III trial in ovarian cancer patients with a complete response after standard first-line chemotherapy. Activating the cancer hosts immune system is a new strategy that is worth being pursued in the fight against ovarian cancer.
Bauerschlag
Dirk O
DO
Department of Gynecology and Obstetrics, University Clinic Schleswig-Holstein, Campus Kiel, Michaelisstrasse 16, 24105 Kiel, Germany. dbauerschlag@hotmail.com
Schem
Christian
C
Baumann
Klaus
K
Harter
Philip
P
Hilpert
Felix
F
Wagner
Uwe
U
du Bois
Andreas
A
Pfisterer
Jakobus
J
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; C518318:abagovomab